Entera Bio Ltd
For the period ended Dec 31, 2023. Filed Mar 8, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 8, 2024
ENTX$3.24-0.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
(U.S. dollars in thousands)
| 2023 | 2022 | |
|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net loss | (8,889) | (13,071) |
| Adjustments required to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 56 | 64 |
| Deferred income taxes | 29 | 174 |
| Share-based compensation | 1,689 | 2,247 |
| Finance income, net | (78) | |
| Changes in operating asset and liabilities: | ||
| Decrease (increase) in accounts receivable | 246 | (63) |
| Decrease (increase) in other current assets | 56 | (40) |
| Increase (decrease) in accounts payable | 66 | (149) |
| Decrease in accrued expenses and other payables | (563) | (1,568) |
| Decrease in contract liabilities | - | (15) |
| Net cash used in operating activities | (7,310) | (12,499) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Funds with respect to employee rights upon retirement | - | (55) |
| Purchase of property and equipment | (17) | (47) |
| Net cash used in investing activities | (17) | (102) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Proceeds from issuance of shares through ATM programs, net of issuance costs | 5 | - |
| Issuance of ordinary shares and warrants due to a private placement | 6,611 | - |
| Issuance costs | (580) | |
| Exercise of options into shares | - | 13 |
| Net cash provided by financing activities | 6,036 | 13 |
| DECREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED DEPOSITS | (1,291) | (12,588) |
| CASH, CASH EQUIVALENTS AND RESTRICTED DEPOSITS AT BEGINNING OF THE YEAR | 12,376 | 24,964 |
| CASH, CASH EQUIVALENTS AND RESTRICTED DEPOSITS AT END OF THE YEAR | 11,085 | 12,376 |
| Reconciliation in amounts on consolidated balance sheets: | ||
| Cash and cash equivalents | 11,019 | 12,309 |
| Restricted deposits included in other current assets | 66 | 67 |
| Total cash and cash equivalents and restricted deposits | 11,085 | 12,376 |
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW TRANSACTIONS: | ||
| Interest received | 18 | - |
| Income taxes paid in cash during the year | - | 165 |
| SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS: | ||
| Issuance costs | 470 | - |
| Operating lease right of use assets obtained in exchange for new operating lease liabilities | 449 | - |
ENTERA BIO LTD.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.